Head-to-head evidence
cagrilintide/semaglutide vs TE-8105
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
cagrilintide/semaglutide · CagriSema
Developed by Novo Nordisk
NCT05394519 · Phase 3 · completed
This was a large, randomized, quadruple-blind, placebo-controlled trial in 1,200 patients using percentage body weight change, the standard efficacy measure for obesity treatment. CagriSema reduced body weight by 13.7% versus 3.4% on placebo, a 10.4-percentage-point difference (p<0.001), meeting the primary endpoint.
Next expected readout: March 2027 · NCT07011667 (registry estimate)
TE-8105
Developed by Immunwork
NCT06471530 · Phase 1/2 · completed
This was an open-label, non-randomized, dose-escalation study with no placebo or control group, so it cannot show whether any effect is attributable to the drug itself. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: cagrilintide/semaglutide's landscape · TE-8105's landscape